The ARHGEF18 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial cell line. This product provides a targeted disruption of the ARHGEF18 gene, enabling loss-of-function studies of this key RhoA guanine nucleotide exchange factor. The polyclonal format ensures a heterogeneous population of knockout cells, suitable for bulk biochemical and cell-based assays without clonal selection bias. Researchers can use these knockout cells to directly interrogate ARHGEF18-dependent signaling pathways and phenotypic outcomes in a genetically defined background.
The parental A-549 cell line was originally established from the lung carcinoma of a 58-year-old male and exhibits hypotriploidy with adherent growth. These cells are widely employed as a model for lung adenocarcinoma and are instrumental in studies of pulmonary epithelial barrier function, drug metabolism, and viral infection. The epithelial characteristics of A-549 cells, including the formation of tight junctions and expression of relevant transporters and metabolizing enzymes, make them a physiologically relevant host for investigating ARHGEF18 function in lung epithelial biology and malignant transformation.
ARHGEF18 encodes a RhoA-specific guanine nucleotide exchange factor that catalyzes the activation of RhoA. Upstream signals such as integrin engagement, GPCR agonists (e.g., LPA, thrombin), and Src/FAK kinases stimulate ARHGEF18-dependent RhoA-GTP loading. Activated RhoA then stimulates ROCK1/2 kinases, which phosphorylate LIMK1/2 and myosin light chain (MLC), leading to cofilin inactivation, actin stress fiber formation, and focal adhesion assembly. Additionally, RhoA-GTP promotes SRF/MRTF transcriptional activity and stabilizes tight junctions via interactions with ZO-1/TJP1, cingulin, actinin, and ERM proteins. Thus, ARHGEF18 links extracellular cues to cytoskeletal reorganization and junctional integrity.
In the A-549 lung adenocarcinoma context, ARHGEF18 is implicated in the regulation of cell migration, invasion, and epithelial barrier maintenance. Disruption of ARHGEF18 in this polyclonal knockout population allows direct interrogation of RhoA-driven processes that contribute to lung cancer metastasis and loss of epithelial integrity. This model is particularly suited for dissecting the role of ARHGEF18 in epithelial-mesenchymal transition (EMT), a key event in carcinoma progression, and for evaluating the impact of ARHGEF18 loss on drug sensitivity and resistance mechanisms commonly studied in A-549 cells.
These polyclonal knockout cells support studies of lung cancer metastasis, epithelial barrier function, and mechanotransduction. Typical assays include western blotting for ARHGEF18 and phospho-MLC, immunofluorescence for ZO-1 and stress fibers, transwell migration/invasion, TEER measurement, RhoA-GTP pulldown, and live-cell actin imaging. Applications also extend to drug screening and GPCR/integrin signaling analysis. For further details, please contact Ascent Research.
